Browsing Tag
RP-A701
1 post
Rocket Pharmaceuticals receives FDA clearance to begin human trials for RP-A701 in treating BAG3-associated dilated cardiomyopathy
Rocket Pharmaceuticals earns FDA IND clearance for RP-A701, advancing gene therapy for rare BAG3-associated dilated cardiomyopathy. Trial begins in U.S.
July 2, 2025